It has been described that HLA-DRB1 is associated with the risk of developing RA, with severity, and with patient mortality, especially in those with positive antibodies such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP). Here, HLA-DRB1 is linked to rheumatoid arthritis.